These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. TP53, MDM2, NQO1, and susceptibility to cervical cancer. Hu X, Zhang Z, Ma D, Huettner PC, Massad LS, Nguyen L, Borecki I, Rader JS. Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):755-61. PubMed ID: 20200430 [Abstract] [Full Text] [Related]
4. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R. Clin Cancer Res; 2007 Jul 15; 13(14):4123-9. PubMed ID: 17634539 [Abstract] [Full Text] [Related]
6. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors. Chien WP, Wong RH, Cheng YW, Chen CY, Lee H. Ann Surg Oncol; 2010 Apr 15; 17(4):1194-202. PubMed ID: 19941079 [Abstract] [Full Text] [Related]
12. Association of rheumatoid arthritis with Mdm2 SNP309 and genetic evidence for an allele-specific interaction between MDM2 and p53 P72R variants: a case control study. Assmann G, Voswinkel J, Mueller M, Bittenbring J, Koenig J, Menzel A, Pfreundschuh M, Roemer K, Melchers I. Clin Exp Rheumatol; 2009 Apr 15; 27(4):615-9. PubMed ID: 19772793 [Abstract] [Full Text] [Related]
14. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. Yu H, Huang YJ, Liu Z, Wang LE, Li G, Sturgis EM, Johnson DG, Wei Q. Mol Carcinog; 2011 Sep 15; 50(9):697-706. PubMed ID: 21656578 [Abstract] [Full Text] [Related]
20. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Nan H, Qureshi AA, Hunter DJ, Han J. Cancer Causes Control; 2009 Mar 15; 20(2):171-9. PubMed ID: 18814047 [Abstract] [Full Text] [Related] Page: [Next] [New Search]